Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Mylan Pharmaceuticals Inc, et al v. Warner Chilcott Public Limited, et al
Case Number:
15-2236
Court:
Nature of Suit:
Companies
- AARP Inc.
- Center for Medicare Advocacy Inc.
- Consumer Action
- Consumer Federation of America
- Indivior PLC
- International Brotherhood of Electrical Workers
- Mayne Pharma Group Ltd.
- Meijer Inc.
- Mylan NV
- National Association of Manufacturers
- National Health Law Program
- Rochester Drug Cooperative Inc.
- Safeway Inc.
- Warner Chilcott Limited
Government Agencies
Sectors & Industries:
-
December 24, 2015
Competition Cases To Watch In 2016
Federal appeals courts are brimming with antitrust cases that could see key decisions in 2016 from continued fighting over the contours of pay-for-delay litigation to a dispute over whether investors can sue over the manipulation of Libor that could trickle down to other benchmark litigation. Here, Law360 looks at the cases attorneys should be watching in 2016.
-
December 23, 2015
Trade Groups Back Warner Chilcott In 3rd Circ. Doryx Row
Generic drugmaker Warner Chilcott PLC received ample support from various industry groups and professors Monday in its efforts to persuade the Third Circuit to reject Mylan Pharmaceuticals Inc.'s bid to revive its suit alleging that Warner Chilcott tried to block generic competition for its acne medication Doryx by tweaking the formula.
-
December 17, 2015
Warner Chilcott Defends Dismissal Of Doryx Case In 3rd Circ.
Warner Chilcott PLC on Tuesday told the Third Circuit that it didn't have the market power to block generic competition for its acne medication Doryx when it pulled the capsules off the market, as Mylan Pharmaceuticals Inc. had accused.
-
October 01, 2015
FTC Pushes 3rd Circ. To Revive Doryx Product-Hopping Case
The Federal Trade Commission has backed Mylan Pharmaceuticals Inc.'s bid to revive allegations that Warner Chilcott PLC tried to block generic competition for its acne medication Doryx by tweaking its formula, telling the Third Circuit a lower court's ruling was based on a misunderstanding of the drug marketplace.
-
September 28, 2015
AAI Backs Mylan's Appeal Of Doryx Product-Hopping Suit
The American Antitrust Institute sided with Mylan Pharmaceuticals Inc. on Friday, urging the Third Circuit to review a district court decision that tossed the generic-drug maker's allegations that Warner Chilcott PLC tried to block generic competition for its acne medication Doryx by tweaking its formula.
- ← Previous
- 1
- 2
- Next →